Stifel analyst Thomas Shrader weighed in on Puma Biotechnology (NYSE: PBYI) after the 20% sell-off in the stock following the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA Trader Talk

After-Hours Stock Movers 05/13: (SHAK) (ISSI) (CTRP) Higher; (PBYI) (GEVO) (FEYE) Lower (more...)May 13, 2015 6:08 PM Puma Biotech (PBYI) Reports Publication of Abstracts for ASCOMay 13, 2015 5:16 PM Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual MeetingMay 13, 2015 5:09 PM